Stealthyx Therapeutics Ltd.

Stealthyx Therapeutics Ltd.

is developing a unique, safe, patented drug-targeting platform technology capable of drug delivery only at sites of disease. This will significantly improve the pharmacokinetic, pharmacodynamic and therapeutic properties of biological agents. Stealthyx has demonstrated that a naturally-occurring system that keeps one particular cytokine, called TGF-beta, in a latent form so that it can only act locally, can be deployed to deliver essentially any payload in a highly targeted manner. The Stealthyx platform provides the ability to take well-validated biological drugs and deliver improved versions which retain the local activity required for efficacy, while eliminating the systemic effects responsible for the undesirable side-effects. The flexible Stealthyx platform has the potential to allow essentially any desired activity profile to be engineered for any biologic drug The company is based in the UK at the Babraham Research Campus and completed a Series A funding round led by Index Ventures in December 2014.